How to Qualify a Chinese Medical-Device Factory After NMPA Announcement 107: Why ISO 13485, MDSAP and a 2014 GMP Certificate Are Not the 1 November 2026 File, What Articles 2–3, 17–21, 32, 91, 104 and 107–113 Require, and Why a Production License or NMPA Registration Is Not China GMP

International medical-device distributors, private-label/OEM procurement executives, and hospital supply chain managers qualifying sterile medical consumables from Chinese manufacturing hubs repeatedly confront commercial sales packets built on regulatory conflation. Factory export representatives routinely present an ISO 13485:2016 certificate issued by a European notified body or international registrar, a Medical Device Single Audit Program (MDSAP) audit report, an active National Medical Products Administration (NMPA) medical-device registration certificate (医疗器械注册证), a provincial Medical Device Production License (医疗器械生产许可证), or a 2014-format China GMP inspection certificate as definitive proof that the facility is fully cleared for ongoing manufacturing. In international tenders and private-label contract negotiations, buyers are frequently assured that 'our quality system is certified to ISO 13485, which exceeds China GMP,' or that 'our provincial production license covers all national manufacturing requirements.'

Under Chinese administrative law, those substitutions fail. On 4 November 2025, the National Medical Products Administration promulgated Announcement No. 107 of 2025, issuing the revised Good Manufacturing Practice for Medical Devices (医疗器械生产质量管理规范)¹. The official English announcement pages confirm the same effective date and the simultaneous repeal of former CFDA Announcement No. 64 of 2014⁴, ⁶. Article 132 of the official 132-article attachment states that the revised standard takes effect on 1 November 2026 and that the 2014 text is repealed on that same date². The announcement text and Article 132 print no extra national grace period after 1 November 2026. The year between publication and the effective date is the implementation window; it is not a grandfathering clause for a 2014 file that remains in use after that date¹, ².

With the 1 November 2026 date now only weeks away, international buyers sourcing sterile consumables—such as single-use circumcision devices, disposable medical laser fibers, surgical staplers, catheter fixation devices, and wound drainage consumables—need a document-level factory file, not a slogan that ISO 13485 or an NMPA product certificate “covers China GMP.” An authentic ISO 13485 certificate or an NMPA product clearance does not, by itself, prove that the plant’s quality manual, personnel roster, verification/confirmation index and release records match Announcement 107. Buyers should audit that file before treating the plant as closed for the next shipment.

This operational buyer guide establishes the exact regulatory framework required to qualify a Chinese medical-device manufacturing facility in 2026. It dismantles the false equivalence between ISO 13485, MDSAP, registration certificates, and China GMP; audits the precise legal reach of Articles 2 and 3; analyzes the substantive file additions introduced across the three new dedicated chapters; details the personnel gates enforced under Articles 17–21 (correcting widespread consultant misinterpretations regarding the legal representative); explains the non-negotiable two-step release architecture under Articles 104, 108, and 113; demonstrates why provincial preparation roadmaps cannot postpone the national deadline; evaluates the draft status of the June 2026 inspection guiding principles; and provides three worked product examples alongside an actionable 8-point incoming supplier checklist.

Table of Contents

• Does ISO 13485, MDSAP, an NMPA registration, a production license or a 2014 GMP certificate replace Announcement 107 after 1 November 2026?
• Who is actually bound under Articles 2 and 3 — registrant, record-filer, contract manufacturer, commissioned R&D, outsourced processing — and does that automatically bind every overseas site?
• What do the three added chapters (quality assurance, verification and confirmation, contract manufacturing) change in the file you should request?
• What do Articles 17–21 actually require for key personnel, and why is 'the legal representative must be full-time' the wrong test?
• How do Articles 104, 108 and 113 split production release from listing release, and why can a quality agreement not move the registrant's duties?
• Do Hubei, Hunan, Fujian or Guangdong provincial plans change the national date, and what should a Shandong 鲁械 buyer ask instead?
• Is the 9 June 2026 inspection guiding principle in force, and what does a draft consultation fail to prove?
• Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber versus Class I aftercare pants, and why NOVACURE is out of scope
• Distributor and OEM incoming checklist, red flags, and the documents to request before 1 November 2026
• Where VEMERIX fits — and where due diligence still begins
• Frequently Asked Questions

Does ISO 13485, MDSAP, an NMPA registration, a production license or a 2014 GMP certificate replace Announcement 107 after 1 November 2026?

The most common operational error committed by international buyers qualifying Chinese medical-device suppliers is treating disparate regulatory instruments as interchangeable tokens of manufacturing compliance. A vendor who presents a folder of authentic international and domestic documents may appear fully qualified on the surface. However, each instrument addresses a completely distinct legal, administrative, or commercial question under sovereign Chinese law¹, ².

To evaluate a factory file rigorously, procurement teams must separate five distinct regulatory instruments:

• ISO 13485:2016 Certificate: ISO 13485 is a voluntary, non-governmental international standard for medical-device quality management systems, audited by commercial certification bodies and accredited under the International Accreditation Forum (IAF) framework. An authentic ISO 13485 certificate demonstrates conformity with international QMS architecture, but it is not sovereign Chinese law, is not audited by Chinese provincial MPAs or the Center for Food and Drug Inspection (CFDI), and is not the 132-article China GMP file. Review why an authentic ISO 13485 certificate is not the China GMP file.
• Medical Device Single Audit Program (MDSAP) Audit Report: MDSAP is a multilateral audit initiative recognized by five participating regulatory authorities: the United States FDA, Health Canada, Australia's TGA, Brazil's ANVISA, and Japan's MHLW/PMDA. The People's Republic of China is not an MDSAP member authority, and the NMPA does not accept an MDSAP audit report in lieu of a Chinese GMP inspection. Holding an MDSAP audit certificate may satisfy a Canadian Medical Device Licence condition or Mexican GMP-certificate reliance, but it is not a substitute for Announcement 107. See why a Canadian MDSAP condition is not Chinese production GMP and why Mexican MDSAP-for-GMP-only is a different file from China Announcement 107.
• NMPA Medical Device Registration Certificate (医疗器械注册证) / Record-Filing (备案凭证): Granted under State Council Decree No. 739 (Regulations for the Supervision and Administration of Medical Devices), an NMPA 注册证 represents premarket marketing clearance for a specific device model and intended use. It verifies that the product's design, technical specifications, and clinical evidence were accepted by the regulatory authority. It does not certify that the physical manufacturing plant is currently operating in compliance with Announcement 107. Review how to verify the NMPA registration certificate that is not a substitute for the 1 November 2026 GMP file.
• Medical Device Production License (医疗器械生产许可证): Issued by the provincial Medical Products Administration (such as Shandong MPA for 鲁-prefix licenses), this administrative permit licenses a corporate entity to manufacture specific device categories at a designated physical address. Holding a valid production license proves that the enterprise obtained initial operating permission, but it does not prove that the plant has updated its quality manual, validated processes, retrained personnel, and instituted two-step release protocols under Announcement 107.
• CFDA Announcement No. 64 of 2014 GMP Certificate / Audit File: Under former regulations, Chinese manufacturers operated under the medical-device GMP established by CFDA Announcement No. 64 on 29 December 2014¹¹. On 1 November 2026, Announcement 64 is formally and completely repealed by Article 132 of Announcement 107¹, ². Any inspection report, self-declaration, or factory dossier pegged to the 2014 standard becomes legally obsolete the moment Announcement 107 takes effect.

Similarly, international buyers must not confuse an export document with manufacturing compliance. While a Certificate of Free Sale (CFS / 医疗器械出口销售证明) issued under NMPA Announcement No. 126 of 2025 certifies that a device is eligible for commercial export, it does not certify that the manufacturing plant has closed its Announcement 107 gap analysis. Review why a Chinese export-sales certificate is not proof that the plant closed the Announcement 107 gap.

Who is actually bound under Articles 2 and 3 — registrant, record-filer, contract manufacturer, commissioned R&D, outsourced processing — and does that automatically bind every overseas site?

To determine who must hold the Announcement 107 technical file, international buyers must analyze the precise statutory language of Articles 2 and 3 of the revised standard. Article 2 establishes the statutory scope of enforcement:

“医疗器械注册人、备案人、受托生产企业（以下简称企业）在医疗器械设计开发、生产、质量控制与产品放行、销售和售后服务等活动过程中应当遵守本规范。” (Medical-device registrants, record-filers and contract manufacturers (hereinafter, the enterprise) shall comply with this standard in the course of medical-device design and development, production, quality control and product release, sales and after-sales service activities.)²— NMPA Announcement No. 107 of 2025, Attachment, Article 2 (unofficial translation; Chinese text controls)

Article 2 names three parties: the registrant (注册人), the record-filer (备案人), and the contract manufacturer (受托生产企业). It then binds those parties in design and development, production, quality control and product release, sales, and after-sales service². It does not print the words 在中华人民共和国境内 (“within the territory of the People’s Republic of China”), does not print an express rule that every overseas manufacturer of imported devices is in scope, and does not print an express overseas-site exemption.

English summaries and AI Overviews sometimes flatten that sentence into “all domestic and foreign companies manufacturing or outsourcing medical devices for the Chinese market.” That slogan is not Article 2. The buyer test is narrower: identify whether the labelled legal manufacturer is a 注册人, 备案人 or 受托生产企业 for the SKU, then request the matching 107 file. Until NMPA issues a dedicated foreign-manufacturer compliance guideline for Announcement 107, treating the 132 articles as an automatic, identical audit checklist for every European or American factory of an imported device over-reads the text. Overseas inspection of imported-device manufacturing remains a separate NMPA instrument family, including the 2018 overseas-inspection rules and the medical-device manufacturing-supervision provisions. Those instruments are not a substitute citation for Article 2.

For a manufacturing site that is a named party under Article 2 and that holds a Chinese Medical Device Production License—including a domestic OEM/ODM, a joint venture, or a wholly foreign-owned enterprise in China—Article 2 prints no export-only exemption. Even if the plant ships 100% of output under private-label contracts, the named-party duty in Article 2 is not displaced by an ISO 13485 certificate or a foreign CE mark².

Moreover, Article 3 expands the operational reach of the quality management system beyond the physical factory walls:

“企业应当按照本规范的要求，结合产品特点，建立健全与所生产医疗器械相适应的质量管理体系，并保证其有效运行。质量管理体系涵盖委托研发、委托生产、外协加工以及委托检验等。” (The enterprise shall, in accordance with this standard and in light of product characteristics, establish and improve a quality management system adapted to the medical devices it manufactures, and ensure that the system operates effectively. The quality management system covers commissioned research and development, contract manufacturing, outsourced processing and entrusted testing.)²— NMPA Announcement No. 107 of 2025, Attachment, Article 3 (unofficial translation; Chinese text controls)

Article 3 therefore requires the QMS to cover commissioned R&D, contract manufacturing, outsourced processing and entrusted testing. Article 9, item (9), separately requires those same activities to be kept under control². A manufacturer cannot ring-fence its quality system to assembly operations while treating sterilization, mould-making or contract laboratories as unmonitored commercial transactions. When qualifying a Chinese supplier, buyers should ask how the QMS qualifies, specifies, audits and traces:

• Commissioned R&D (委托研发): External design institutes, clinical research organizations (CROs), or engineering contractors developing product specifications, molds, or software architecture.
• Contract Manufacturing (委托生产): Sub-tier manufacturing partners producing subassemblies, specialized components, or executing partial production stages.
• Outsourced Processing (外协加工): Specialized external processes critical to sterile single-use devices, including contract ethylene oxide (EO) sterilization, gamma irradiation, electron-beam processing, cleanroom injection molding, or precision extrusion.
• Entrusted Testing (委托检验): Third-party accredited testing laboratories performing biological evaluation (ISO 10993 cytotoxicity, sensitization, systemic toxicity), sterility assurance testing, bacterial endotoxin testing (LAL / TAL), packaging seal integrity validation, and shelf-life accelerated aging.

When qualifying a Chinese supplier, buyers must verify that the vendor's QMS directly governs and audits every outsourced sterilization provider and contract testing lab under Article 3, rather than simply filing a third-party test report without internal quality verification. To understand how outsourced manufacturing files are audited under comparative international frameworks, compare why a QMSR purchasing file is not a China GMP file and who is the labelled manufacturer whose China GMP and listing-release duties cannot be signed away.

What do the three added chapters (quality assurance, verification and confirmation, contract manufacturing) change in the file you should request?

As reported by NMPA on 4 November 2025 and restated on the official English revision page of 24 December 2025, the revised GMP has 15 chapters and 132 articles and adds dedicated chapters on quality assurance, verification and confirmation, and contract manufacturing and outsourced processing³, ⁵. The 2014 CFDA text on nmpa.gov.cn is 13 chapters and 84 articles, not 12¹¹. CFDI published a before/after comparison notice on 5 November 2025; NMPA also issued a graphic-interpretation series beginning 10 November 2025. Neither is a substitute for the 132-article attachment⁷, ¹⁰.

A line-by-line review of the official statutory attachment reveals the specific technical mandates introduced across these three added chapters:

• Chapter 2: Quality Assurance (质量保证, Articles 7–13): Quality assurance is a dedicated chapter rather than a blended general provision. Article 9 requires a quality-assurance system and complete QMS documentation covering, among other items, design/production/QC conformity, controlled intermediates, verification/confirmation, batch release after review and approval, and controlled commissioned R&D, contract manufacturing, outsourced processing and entrusted testing. Articles 10–13 require change control, continuing improvement through quality-data monitoring, CAPA, internal audit and management review, and lifecycle quality-risk management². Article 15, in Chapter 3, separately gives the quality department a product-quality veto (否决权); that veto is not written as a Chapter 2 slogan.
• Chapter 9: Verification and Confirmation (验证与确认, Articles 69–77): Chapter 9 unifies verification (验证) and confirmation (确认). Article 69 requires the scope and extent to be set from risk assessment. Article 71 requires documented evidence that premises, facilities and equipment are designed, installed and operated for their intended use. Article 72 requires process verification/confirmation to show that specified process parameters can consistently produce conforming product; special processes shall be confirmed and key processes verified. Article 76 requires a verification/confirmation plan and an approved scheme covering the object, responsibilities, methods, sampling and acceptance criteria. Article 76 does not use the English terms Validation Master Plan, DQ, IQ, OQ or PQ. Article 77 states: “设计开发、生产、检验、仓储等过程中采用的计算机软件对产品质量有影响的，企业应当进行确认并保留记录和结论。软件确认至少包括首次使用前的确认、更改后必要的再确认等，确认或者再确认的方法和活动应当与软件使用的风险相适应。” (Where computer software used in design and development, production, inspection or warehousing affects product quality, the enterprise shall confirm it and retain records and conclusions. Software confirmation shall at least include confirmation before first use and necessary reconfirmation after change; methods shall be commensurate with software-use risk.)²
• Chapter 12: Contract Manufacturing and Outsourced Processing (委托生产与外协加工, Articles 107–116): Article 109 requires an on-site assessment of the contractor’s production, quality-assurance and risk-management capability before contract manufacturing, and periodic on-site audit during the term. Article 110 requires the delegating party to staff a quality function that can monitor the contracted activity; it does not print a “technical-transfer documentation” clause. Article 108 and Article 113 then lock listing-release duties to the delegating party, as the next section sets out².

In addition to the three new chapters, Announcement 107 upgrades key technical baselines across facilities, documentation, and traceability:

• Cleanroom static pressure differentials (Article 32): Where the production environment has cleanliness-grade requirements, the static pressure difference between clean and non-clean areas shall be greater than 10 Pa, and the difference between different cleanliness grades shall be greater than 5 Pa². Article 32 does not limit that rule to sterile single-use devices, and it does not require “continuous digital” logging as the statutory form. Buyers should still request the plant’s pressure-differential records and HVAC qualification reports where cleanliness grades apply.
• Electronic records (Article 46): Where information-management methods are used, the enterprise shall ensure that electronic records or data are true, accurate, complete, timely and traceable, including user-permission control, authorised change/deletion with retained records, backup, and electronic-signature rules where used². Shared logins and back-dated records are buyer red flags; they are not labelled “immediate critical deficiencies” in Article 46 itself.
• Unique Device Identification (Article 91): Enterprises shall carry out UDI coding (赋码), data upload and maintenance/updating in accordance with national UDI implementation requirements, and shall keep the information true, accurate, complete and traceable². Article 91 is a pointer to those national UDI rules; it does not by itself require every Class I or exempt SKU to carry UDI overnight. Review why Article 91 is a China UDI-implementation pointer, not a second EUDAMED deadline article. Label-symbol clocks such as EU REP artwork belong in a different file; see why an EU REP symbol clock is not the Chinese factory GMP file.

What do Articles 17–21 actually require for key personnel, and why is 'the legal representative must be full-time' the wrong test?

Personnel qualification is one of the most frequently tested areas in a Chinese factory file. Chapter 3 (Organization and Personnel, Articles 14–24) sets the roster, dual-hat ban, class-dependent education gates and the product-release reviewer’s independence².

Article 17 defines the mandatory roster of key management personnel:

“企业应当配备与所生产产品相适应的关键岗位人员。关键岗位人员至少应当包括企业法定代表人、主要负责人、管理者代表、生产管理部门负责人、质量管理部门负责人和产品放行审核人等，企业主要负责人、管理者代表、生产管理部门负责人、质量管理部门负责人和产品放行审核人应当为企业的全职人员。关键岗位人员应当熟悉医疗器械相关法律法规，具有质量管理的实践经验，有能力对生产管理和质量管理中的实际问题作出正确的判断和处理。” (The enterprise shall appoint key-post personnel adapted to the products it manufactures. Key-post personnel shall at least include the legal representative, the principal responsible person, the management representative, the production-management head, the quality-management head and the product-release reviewer. The principal responsible person, management representative, production-management head, quality-management head and product-release reviewer shall be full-time personnel of the enterprise. Key-post personnel shall be familiar with medical-device laws and regulations, have quality-management practice, and be able to judge and handle actual production- and quality-management problems.)²— NMPA Announcement No. 107 of 2025, Attachment, Article 17 (unofficial translation; Chinese text controls)

Consultancy comparison tables in late 2025 often reported that “the legal representative must now be a full-time employee.” Article 17 does not say that. It names the legal representative (法定代表人) in the opening list of key-post personnel. The next clause, which requires full-time (全职) status, names five operational roles and omits the legal representative². Article 17 also does not print “shall not hold concurrent posts in other enterprises” (不得在其他企业兼职). That extra ban is a consultancy gloss, not the Chinese sentence. Under company law the legal representative is a statutory officer and may sit in a group structure; the 107 full-time test is the five operational roles, not that officer.

Article 14 separately forbids dual-hatting production and quality leadership: “生产管理部门和质量管理部门负责人不得互相兼任” (The heads of the production-management department and the quality-management department shall not concurrently hold each other’s posts)². On and after 1 November 2026, a single factory manager filling both seats is a file defect against Article 14. That is a buyer send-back; the article does not itself print “immediate inspection failure.”

Furthermore, Articles 19, 20, and 21 establish class-dependent educational degrees and professional experience gates for the operational leadership team:

How do Articles 104, 108 and 113 split production release from listing release, and why can a quality agreement not move the registrant's duties?

For international distributors procuring devices under private-label brands or OEM/ODM arrangements, the most dangerous operational breakdown under Announcement 107 involves product release. In traditional contract manufacturing, Western buyers often assume that once the Chinese contract manufacturer's quality control department inspects the batch and stamps a certificate of conformity (合格证), the product is legally released for shipment.

Announcement 107 fundamentally dismantles this practice by formalizing a mandatory two-step release protocol under Article 104:

“委托生产的，产品放行包括生产放行和上市放行。医疗器械注册人、备案人负责上市放行，受托生产企业负责生产放行。” (In contract manufacturing, product release includes production release and listing release. The medical-device registrant or record-filer is responsible for listing release; the contract manufacturer is responsible for production release.)²— NMPA Announcement No. 107 of 2025, Attachment, Article 104, last paragraph (unofficial translation; Chinese text controls)

Article 104 first sets a general product-release procedure (process completed, complete batch and QC records, special situations closed, labelling/UDI in order, authorised release personnel, accompanying certificate of conformity). Only the last paragraph splits contract manufacturing into two gates²:

• Gate 1: Production release (生产放行): The contract manufacturer is responsible. Article 113 requires the contractor to write a production-release procedure, review manufacturing and QC records against stated criteria, and obtain an authorised release signature before the product leaves the plant². EO charts, biological indicators and residual-EO limits belong in the registered process and in the records the reviewer actually checks; they are not copied into Article 104 as a statutory list.
• Gate 2: Listing / market release (上市放行): The registrant or record-filer is responsible. Article 113 requires the delegating party to write a listing-release procedure and to review manufacturing records, QC records and the contractor’s production-release file before an authorised release signature².

Article 108 and Article 113 then stop the quality agreement from moving those duties. Article 108: “委托方不得通过协议转移依法应当由其履行的义务和责任。” (The delegating party shall not transfer through an agreement the obligations and responsibilities that it is legally required to perform.)² Article 113: “产品上市放行由委托方自行完成，不得委托其他企业进行。” (Product listing release shall be completed by the delegating party itself and shall not be delegated to another enterprise.)²

If a commercial quality agreement says the contract manufacturer “shall execute finished-product release on behalf of the registrant, and separate registrant release is waived,” that clause cannot transfer the Article 108 and 113 duties. A shipment whose listing release was signed only at the CMO is a file that fails the two-step test. Administrative consequences for illegal manufacture or release sit in the Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739) and related enforcement rules; this article does not invent a seizure-and-recall script from Article 104 alone. Review who is the labelled manufacturer whose China GMP and listing-release duties cannot be signed away.

Do Hubei, Hunan, Fujian or Guangdong provincial plans change the national date, and what should a Shandong 鲁械 buyer ask instead?

In an effort to rationalize compliance preparation, several provincial Medical Products Administrations have issued provincial implementation roadmaps for Announcement 107. These documents have generated widespread confusion among international distributors, with many foreign buyers mistakenly believing that China has granted regional extensions or postponed national enforcement.

The sourced provincial example is Hubei. The Hubei Provincial Medical Products Administration notice of 30 January 2026 (posted 2 February 2026), 新版《医疗器械生产质量管理规范》推进实施方案, is a four-stage local implementation plan, not a national amendment of Article 132⁹:

• Stage 1 (Mobilisation and training, January–May 2026): Provincial mobilisation, regulator and key-personnel training by the end of March, local full-coverage enterprise training by the end of April, and enterprise all-staff training by the end of May⁹.
• Stage 2 (Enterprise self-inspection and upgrade, June–October 2026): Enterprises shall complete a clause-by-clause gap analysis and a rectification plan by the end of June 2026, and shall complete at least one full internal audit and management review of the new system by the end of October 2026⁹.
• Stage 3 (Guidance and spot-check, June–October 2026): Local regulators are to spot-check enterprise self-inspection and rectification at a rate of not less than 30 percent and to finish the first round of that verification by the end of October 2026⁹. That 30 percent figure is a pre-deadline supervisory sample in Hubei, not a national post-1-November inspection quota.
• Stage 4 (Full implementation from 1 November 2026): From 1 November 2026, enterprise QMS in the province shall fully meet the revised standard. Hubei then uses flight inspections and routine supervision against the new text; it does not move Article 132⁹.

Other provinces have published their own preparation notices. Those local clocks still do not amend Article 132. Hubei’s June gap-analysis date and October internal-audit target are Hubei supervisory milestones. They do not grant an extra day after 1 November 2026. Announcement 107 is an NMPA normative document; a provincial bureau cannot rewrite Article 132¹, ². This article cites Hubei as the worked provincial example and does not treat unsourced Hunan, Fujian or Guangdong dates as if they were verified here.

This distinction is critical for buyers qualifying medical-device manufacturers in Shandong Province—the home of major sterile consumable clusters in Weihai, Jinan, and Zibo, whose products carry the 鲁械 (Lu-Xie) registration and licensing prefix. As of September 2026, the Shandong Provincial Medical Products Administration has not published a public staggered-milestone roadmap identical to Hubei's scheme. A Shandong manufacturer cannot cite Hubei's or Hunan's preparatory notices to excuse incomplete validation files. When auditing a Shandong manufacturing facility, buyers must demand:

• A completed, company-specific Announcement 107 Gap Analysis Report and Verification Matrix signed by the Management Representative and Quality Head.
• Full internal audit and management review records executed specifically against the 15 chapters and 132 articles of Announcement 107.
• Written confirmation from the supplier regarding its communication with local municipal and provincial Shandong MPA inspection branches concerning Announcement 107 audit readiness.

Is the 9 June 2026 inspection guiding principle in force, and what does a draft consultation fail to prove?

During supplier audits, factory representatives and third-party audit brokers may attempt to demonstrate compliance by presenting mock audit scorecards referencing the '2026 NMPA Medical Device GMP Inspection Guiding Principles.' International buyers must exercise extreme diligence regarding the legal standing of this document.

On 9 June 2026, the NMPA General Department opened a public consultation on 医疗器械生产质量管理规范检查指导原则（征求意见稿） (Medical Device Good Manufacturing Practice Inspection Guiding Principles — Draft for Comment), with comments to 24 June 2026 at mdgmp@cfdi.org.cn⁸. The consultation page identifies the draft and two Word attachments. It does not itself enact inspection scoring.

As of 8 September 2026, this review did not locate a later final, binding inspection guiding principle replacing that consultation⁸. A 征求意见稿 is not in-force inspection law. Provincial inspectors cannot treat draft scoring categories as a published certificate, and a supplier who presents a “certificate of compliance with the 2026 Inspection Guiding Principles” is presenting a marketing artifact until a final instrument exists.

Buyers may read the draft attachment as intelligence about how NMPA might later score inspections. They should not quote draft item counts, key/major/general splits, or “conforms / rectify / fails” thresholds as if those numbers were already law. Official legal compliance on 1 November 2026 is measured against the 132 articles of Announcement 107, not against a consultation draft², ⁸.

Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber versus Class I aftercare pants, and why NOVACURE is out of scope

To understand how Announcement 107 applies to specific procurement portfolios, consider three distinct sterile and consumable product scenarios across minimally invasive surgery and urology:

• Worked example 1: CE-marked circumcision ring (VEMERIX Circumcision Device): The public product page records an NMPA Class II device (鲁械注准20172020238), CE yes, and ethylene-oxide sterilization¹². That page does not publish an EU MDR 2017/745 notified-body certificate number. A distributor shipping the ring into Europe cannot treat CE plus ISO 13485 as a substitute for the China GMP file of the Weihai, Shandong manufacturing site. Personnel rosters (Articles 17–22), cleanliness-grade pressure records where applicable (Article 32), sterilization confirmation under Chapter 9, and two-step release where contract manufacturing applies must still match Announcement 107 on 1 November 2026. Review why a circumcision-device registration pack is not the 1 November 2026 factory GMP file.
• Worked example 2: NMPA-only laser fiber (VEMERIX Disposable Medical Laser Fiber): The public product page records an NMPA Class II sterile consumable (鲁械注准20192010517) for 1470 nm endovenous laser workflows, without a Medison CE claim¹³. The factory question is the China GMP file for that fiber. Buyers must not inherit CE or factory-audit evidence from the partner-supplied NOVACURE diode laser console. NOVACURE is a partner-supplied capital source; the disposable fiber is Medison’s NMPA-registered consumable. Review why an NMPA-registered laser fiber cannot inherit CE or GMP evidence from the partner console.
• Worked example 3: Class I aftercare garment (Circum-CARE post-op protective pants): The public catalogue records Circum-CARE pants as an NMPA Class I device with municipal filing 鲁威械备20190014. Under Articles 19 and 20, Class I education gates for the management representative and quality head are a relevant college diploma (大专), not the Class II/III bachelor’s or mid-level-title gate². If one factory makes both Class I garments and Class II sterile rings under a shared licence, the Class II line still uses the higher education gates. Do not treat all post-operative underwear as Class I; this row is the labelled VEMERIX SKU, not a universal classification opinion.

Distributor and OEM incoming checklist, red flags, and the documents to request before 1 November 2026

To ensure thorough due diligence before 1 November 2026, international distributors, private-label brand owners, and OEM buyers should demand the following 8-point documentary evidence package from every Chinese medical-device supplier:

• 1. Announcement 107 Quality Manual: An updated Quality Manual formally cross-referenced to the 15 chapters and 132 articles of NMPA Announcement No. 107 of 2025, demonstrating explicit retirement of legacy CFDA Announcement No. 64 references.
• 2. Key Personnel Roster & Appointment Dossiers: Formal corporate appointment letters, degree certificates, and local social security payment records verifying that the Principal Responsible Person, Management Representative, Quality Head, Production Head, and Product-Release Reviewer are full-time employees satisfying Articles 17–21, with documented separation of Production and Quality heads under Article 14.
• 3. Two-Step Release SOP & Release Forms: Standard Operating Procedures establishing the procedural separation between Production Release (生产放行) by the manufacturing facility and Listing Release (上市放行) by the legal registrant, accompanied by sample executed release certificates complying with Article 104.
• 4. Contract Manufacturing Agreement (where applicable): For outsourced manufacturing, an executed Quality Agreement confirming compliance with Chapter 12 and explicitly stating that statutory listing release duties cannot be delegated to the contract manufacturer under Articles 108 and 113.
• 5. Chapter 9 verification/confirmation index: The Article 76 plan and approved schemes, plus reports for special-process confirmation and key-process verification. For EO-sterilized SKUs, include the current sterilization confirmation file. Do not accept “VMP / IQ/OQ/PQ” as a substitute label unless the underlying Article 76 records exist.
• 6. Article 77 software-confirmation records: Confirmation records and conclusions for computer software used in design, production, inspection or warehousing that affects product quality, including confirmation before first use and reconfirmation after change.
• 7. Article 32 pressure-differential records (where cleanliness grades apply): Records showing static differentials greater than 10 Pa between clean and non-clean areas and greater than 5 Pa between different cleanliness grades, plus the plant’s HVAC qualification reports.
• 8. Announcement 107 Gap Analysis & Internal Audit Report: A completed, executive-signed gap analysis matrix detailing the manufacturer's transition from the 2014 standard to Announcement 107, backed by full internal audit and management review meeting minutes.

Conversely, buyers should treat any of the following occurrences as an immediate critical red flag warranting postponement of orders or technical escalation:

• Red Flag 1: The supplier claims that its ISO 13485:2016 certificate or MDSAP audit report exempts the factory from updating its China GMP documentation.
• Red Flag 2: The factory's quality manual still cites CFDA Announcement No. 64 of 2014 as its active governing manufacturing standard.
• Red Flag 3: The production manager and the quality manager are the same individual, directly violating Article 14.
• Red Flag 4: In a contract manufacturing arrangement, the quality agreement purports to transfer finished-product listing release entirely to the contract manufacturer, violating Articles 108 and 113.
• Red Flag 5: The manufacturer presents a Hubei or Hunan provincial preparatory roadmap as justification for why its factory in Shandong or Jiangsu has not closed its validation files.
• Red Flag 6: The vendor presents a 'certificate of conformity' referencing the 9 June 2026 draft inspection guiding principles as an official in-force government license.

Where VEMERIX fits — and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Weihai Medison is a Chinese NMPA-registered manufacturer of sterile single-use devices. CE marking is recorded on the circumcision-device product page and is not a portfolio-wide claim.

The relevant SKUs for this factory-file question are the CE-marked VEMERIX Circumcision Device (NMPA Class II, 鲁械注准20172020238, EO-sterilized self-detaching ring), the disposable circumcision stapler (NMPA Class II, no CE field on the public page), Circum-CARE post-op pants (NMPA Class I municipal filing), and NMPA-registered disposable medical laser fibers for endovenous workflows. NOVACURE remains a partner-supplied laser source and is not a Medison-manufactured capital system.

VEMERIX does not claim that an ISO 13485 certificate or a European CE mark replaces Chinese manufacturing obligations, and this page does not publish a 107 inspection conclusion or a Shandong MPA close-out score. Due diligence still begins with the buyer’s reading of Announcement 107 and the 132-article attachment. Qualified distributors, private-label OEM partners and procurement teams can request the current quality manual, personnel roster, verification/confirmation index and quality-agreement terms through Quality or Contact.

To request the current Announcement 107 technical pack, a quality-agreement discussion or an on-site visit in Weihai, use the quality page or the contact form.

Frequently Asked Questions

Does an ISO 13485 certificate mean the Chinese factory meets NMPA GMP after 1 November 2026?

No. ISO 13485:2016 is an international, voluntary quality-management standard audited by independent commercial certification bodies. It is not Chinese law, is not audited by Chinese provincial MPAs or CFDI as China GMP, and does not by itself enforce Articles 17–22 personnel gates, Article 32 pressure differentials, or Articles 104 and 113 two-step release. An authentic ISO 13485 certificate is useful export evidence, but it is not a substitute for the Announcement 107 file. Review why an authentic ISO 13485 certificate is not the China GMP file.

Does MDSAP replace China medical-device GMP?

No. China is not a participating MDSAP authority. The current participating authorities are the US FDA, Health Canada, Australia’s TGA, Brazil’s ANVISA and Japan’s MHLW/PMDA. NMPA does not accept an MDSAP audit report as a substitute for Chinese GMP. An MDSAP certificate may still matter for a Canadian licence or for Mexican GMP-certificate reliance; those are different files. See why a Canadian MDSAP condition is not Chinese production GMP and why Mexican MDSAP-for-GMP-only is a different file from China Announcement 107.

Was there a national grace period after Announcement 107?

No. NMPA Announcement No. 107 of 2025 was published on 4 November 2025, providing an effective date of 1 November 2026—granting an intentional 12-month implementation window. Article 132 of the official statutory attachment explicitly repeals former CFDA Announcement No. 64 of 2014 on that exact same day. Neither the announcement nor the statutory articles provide any additional national grace period or transitional delay. On 1 November 2026, compliance with all 132 articles becomes mandatory across China.

Is the legal representative required to be a full-time employee under Article 17?

No. Article 17 names the legal representative as key-post personnel, then requires full-time (全职) status for the principal responsible person, management representative, production head, quality head and product-release reviewer. The legal representative is not in that full-time sentence. Article 17 also does not print a ban on concurrent posts in other enterprises. Do not fail a file solely because the legal representative is not a full-time employee.

If I buy from a contract manufacturer, whose signature is listing release?

Under Articles 104 and 113, listing release (上市放行) is the registrant’s or record-filer’s duty. The contract manufacturer performs production release (生产放行). Article 108 forbids transferring legally required duties by agreement, and Article 113 says listing release shall be completed by the delegating party itself and shall not be delegated to another enterprise. If only the CMO signed listing release, the two-step file is not closed.

Does a Hubei or Hunan provincial plan apply to a factory in Shandong?

No. Implementation schemes issued by provincial authorities—such as Hubei MPA's notice establishing a June 2026 gap-analysis deadline and an October internal audit milestone—apply strictly to enterprises under that specific provincial bureau's supervision. Furthermore, provincial roadmaps do not alter the national 1 November 2026 effective date. A factory in Shandong Province (bearing a 鲁械 prefix) is supervised by Shandong MPA and must achieve complete, uncompromised compliance across all 132 articles by 1 November 2026 without reference to another province's preparatory schedule.

Does an NMPA registration certificate prove the plant is GMP-compliant?

No. An NMPA medical-device registration certificate (医疗器械注册证) is a premarket product approval under State Council Decree No. 739. It certifies that the device's technical specifications, design safety, and clinical data satisfy regulatory requirements for market clearance. It does not certify that the factory's daily manufacturing operations, ongoing batch records, personnel rosters, and cleanroom HVAC controls conform to Announcement 107. Manufacturing compliance is governed by the factory's Production License and dynamic China GMP technical file.

Does VEMERIX already hold a published 107 inspection conclusion for these SKUs?

No. This page does not claim a published government inspection conclusion under Announcement 107, and no Chinese manufacturer can treat a 2014 inspection report as that conclusion. Weihai Medison operates under a Shandong MPA production licence and can discuss the current quality manual, personnel roster, verification/confirmation index and quality-agreement terms. Buyers should still read Announcement 107 themselves rather than accept a claimed 107 certificate number.